224 related articles for article (PubMed ID: 17687199)
1. [Bevacizumab (Avastin)].
Yamazaki K; Yoshino T; Boku N
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1183-91. PubMed ID: 17687199
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab in the treatment of colorectal cancer.
Marshall JL
Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):8-9. PubMed ID: 17491585
[No Abstract] [Full Text] [Related]
3. Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.
Heinemann V; Hoff PM
Oncology; 2010; 79(1-2):118-28. PubMed ID: 21088438
[TBL] [Abstract][Full Text] [Related]
4. [A case with liver resection of metastasis from rectal cancer after bevacizumab treatment].
Nishida K; Matsuyama T; Masuda D; Hosokawa T; Tokita H; Kakimoto M; Goto H; Yoshimura T; Koshiishi H; Okamura T
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2517-9. PubMed ID: 21224625
[TBL] [Abstract][Full Text] [Related]
5. Update: NCCN colon and rectal cancer clinical practice guidelines.
Kiel K; Engstrom PF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 3():S-14-8. PubMed ID: 23570093
[No Abstract] [Full Text] [Related]
6. [Treatment of advanced and/or metastatic colorectal cancer with bevacizumab in combination with oxaliplatin-based chemotherapy (Folfox7 regimen)].
Oukkal M; Djilat K; Hadjam RM; Mahgoun M; Bentabak K; Graba A; Smail N; Kaci NA; Ahmed RB; Bouzid K
Bull Cancer; 2010 Apr; 97(4):469-74. PubMed ID: 20385517
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
Hurwitz H; Kabbinavar F
Oncology; 2005; 69 Suppl 3():17-24. PubMed ID: 16301832
[TBL] [Abstract][Full Text] [Related]
8. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
Dohn LH; Jensen BV; Larsen FO
Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
[No Abstract] [Full Text] [Related]
9. [Up to date chemotherapy for colon cancer].
Kubota T; Wada N; Kitajima M
Nihon Shokakibyo Gakkai Zasshi; 2007 Feb; 104(2):177-85. PubMed ID: 17283411
[No Abstract] [Full Text] [Related]
10. The future development of bevacizumab in colorectal cancer.
Díaz-Rubio E; Schmoll HJ
Oncology; 2005; 69 Suppl 3():34-45. PubMed ID: 16301834
[TBL] [Abstract][Full Text] [Related]
11. Highlights from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2006.
Clin Colorectal Cancer; 2006 Jul; 6(2):109-13. PubMed ID: 16945165
[No Abstract] [Full Text] [Related]
12. Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer.
Klamerus JF; Brahmer JR
Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S51-6. PubMed ID: 21884999
[TBL] [Abstract][Full Text] [Related]
13. Adding a humanized antibody to vascular endothelial growth factor (Bevacizumab, Avastin) to chemotherapy improves survival in metastatic colorectal cancer.
Clin Colorectal Cancer; 2003 Aug; 3(2):85-8. PubMed ID: 12952562
[No Abstract] [Full Text] [Related]
14. [IDEA study (International Duration Evaluation of Adjuvant Chemotherapy) for patients with stage III colon cancer: Possibility of reducing to 3 months treatment for 60% of the patients!].
André T; Taieb J;
Bull Cancer; 2018 Jun; 105(6):546-547. PubMed ID: 29776587
[No Abstract] [Full Text] [Related]
15. Bevacizumab for advanced colorectal cancer.
Hadj Tahar A
Issues Emerg Health Technol; 2004 Dec; (63):1-4. PubMed ID: 15612152
[TBL] [Abstract][Full Text] [Related]
16. Accrual delayed in adjuvant bevacizumab trial.
Tuma RS
J Natl Cancer Inst; 2006 Apr; 98(7):439-40. PubMed ID: 16595779
[No Abstract] [Full Text] [Related]
17. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
Hochster HS
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S8-14. PubMed ID: 17145525
[TBL] [Abstract][Full Text] [Related]
19. Lessons from the adjuvant bevacizumab trial on colon cancer: what next?
Van Cutsem E; Lambrechts D; Prenen H; Jain RK; Carmeliet P
J Clin Oncol; 2011 Jan; 29(1):1-4. PubMed ID: 21115866
[No Abstract] [Full Text] [Related]
20. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
